Kenya is set to become the first country in East Africa to develop a region-specific snake antivenom, with the project expected to be completed by the end of 2026. The initiative, backed by the National Assembly Departmental Committee on Health, aims to address the public health risk posed by the limited availability of antivenoms suited to local snake species.
The country records over 19,000 snakebite cases annually, many of which require treatment with antivenoms that are not always effective against the venom of local snakes. This gap in medical response has prompted Kenya to invest in research and production of a tailored antivenom. The project involves collaboration between local scientists and health authorities to ensure the new treatment is both effective and accessible.
The push for a region-specific antivenom comes amid growing awareness of the dangers posed by snakebites in East Africa. Snake species found in the region, such as the puff adder and the black mamba, are responsible for a significant proportion of these incidents. The development of a locally produced antivenom is seen as a critical step in improving emergency care and reducing mortality rates.
This effort aligns with broader regional health goals, as Kenya seeks to lead in medical innovation for the East African community. The success of the project could set a precedent for other countries in the region to follow, potentially reducing reliance on imported antivenoms and improving treatment outcomes.
